Mavorixafor

Phase 3

X4 Pharmaceuticals, Inc (XFOR)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in WHIM Syndrome

View Full Landscape

Drug Information

Target Indication

WHIM Syndrome

Clinical Trial

NCT03995108

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/27/2026

Xolremdi

Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

XFOR

X4 Pharmaceuticals, Inc

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

X4P-001Phase 2

WHIM Syndrome

axitinibPhase 2

Clear Cell Renal Cell Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts